Clinical Trial

Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure (SANDI STUDY)

Study acronym: SANDI
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 29, 2025 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to assess the natriuretic effect of intravenous acetazolamide in patients admitted with heart failure and persistent congestion despite treatment with intravenous furosemide and sodium-glucose cotransporter type 2 (iSGLT2) inhibitors. The main question it aims to answer is whether there is a difference in natriuresis 24 hours after acetazolamide association to medical treatment recommended by the guidelines (furosemide and ISGLT2).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-28; most recent amendment 2025-12-19.
Status change: Not Yet Recruiting → Recruiting 2025-12-19
Trial Details
NCT Number NCT06285760
Lead Sponsor Puerta de Hierro University Hospital
Collaborators: Hospital Clinic of Barcelona, Hospital Central de la Defensa Gómez Ulla, Hospital Vall d'Hebron, Hospital Universitario Ramon y Cajal, University Hospital of Girona Dr. Josep Trueta, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Conditions Heart Failure, Persistent Congestion
Enrollment 64 participants
Start Date 2024-03-01
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-29